Curis Inc.: Understanding CI-8993 And VISTACrowd Noise FundamentalsWed, Jan. 27, 20214 Comments Curis Inc.: Understanding CA-4948 And IRAK-4 InhibitionCrowd Noise FundamentalsWed, Dec. 23, 202017 Comments The Only Way To Play CurisGary BourgeaultFri, Jun. 12, 20208 Comments Share your Analysis...
Curis还在对急性髓系白血病和骨髓增生异常综合征患者的I/II期试验中对CA-4948进行评估,并已获得美国食品和药物管理局(FDA)的孤儿药物指定。 此外,Curis还与ImmuNext合作开发了CI-8993,这是一种抗VISTA的单克隆抗体,目前正在实体瘤患者中进行1期试验。Curis也是与罗氏集团(Rochegroup)成员Genentech合作方,合作包括正在...
In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the tre...
and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currentl...
Curis traded at $15.58 this Tuesday April 9th, decreasing $0.92 or 5.58 percent since the previous trading session. Looking back, over the last four weeks, Curis lost 50.53 percent. Over the last 12 months, its price rose by 20.05 percent. Looking ahead, we forecast Curis to be priced at...
Curis, Inc. announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.
In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a me...